Find the latest Biogen Inc. (BIIB) stock quote, history, news and other vital Zacks · HealthEquity's First-Quarter Revenue and Earnings Fall Short of Estimates. Get the latest Biogen Inc. (BIIB) stock news and headlines to help you in your trading Zacks.com featured highlights include: Canadian Solar, Biogen, Graphic Jun. 3, 2020 at 12:31 p.m. ET on Zacks.com BIIB Stock News and Research Articles - Biogen : latest news, headlines and Surmodics Gets CE Mark for SurVeil Drug-Coated Balloon - www.zacks.com. BIIB Analysis. This page features the latest analysis and reports for the Biogen Inc stock. Zacks View detailed stock price information for Biogen Inc. [BIIB:US] from TMXmoney including charting Trade BIIB:US Now Zacks , 9:50 AM EDT June 10, 2020
Earnings Biogen (NASDAQ:BIIB) Earnings Information. Biogen last issued its earnings results on April 22nd, 2020. The biotechnology company reported $9.14 EPS for the quarter, beating the consensus estimate of $7.73 by $1.41.
BIIB Stock Message Board for Investors. Biogen Inc. Stock Price, News and Company Updates. Message Board Total Posts: 102 Find the latest BIOGEN INC (BIIB.MX) stock quote, history, news and other vital information to help you with your stock trading and investing. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Biogen (BIIB) Stock Down Despite Q1 Earnings & Sales Beat ...
In 2018, Biogen paid $217 million for an ALS drug candidate from Karyopharm. The company was founded in 1978 by a group that included two Nobel Prize winners and is headquartered in Cambridge Earnings Biogen (NASDAQ:BIIB) Earnings Information. Biogen last issued its earnings results on April 22nd, 2020. The biotechnology company reported $9.14 EPS for the quarter, beating the consensus estimate of $7.73 by $1.41. Earnings estimates and surprises for Biogen Inc (BIIB) are an important tool used to evaluate the company's overall strength and value of the stock. Biogen (NASDAQ: BIIB) hasn't been the world's most reliable biotech stock over the past five years. Major setbacks in its Alzheimer's disease drug-development pipeline have crimped growth, and the withdrawal from the market of its multiple sclerosis drug Zinbryta caused potential investors to be skeptical. Indeed, investing in Biogen in 2016 A picture's worth a mountain of numbers- and our charts are excellent for isolating and highlighting a security's key leverage points, liberating them from the rows and columns of numbers and ratios in which they are often buried. Most charts are focused on price action - which is valuable for Amgen Inc. (AMGN) : Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research Biogen (BIIB) Stock Down Despite Q1 Earnings & Sales Beat Zacks: 09:26AM : Recap: Biogen Q1 Earnings Benzinga: 09:20AM : Biogen Earnings Top Forecasts, but the Stock Is Falling on Its Alzheimers-Drug Delay Barrons.com: 09:07AM : Biogen Announces 1Q20 Beat, But Aducanumab Update Steals The Show SmarterAnalyst: 08:32AM
BIIB Dividend History & Description — Biogen Inc. Biogen is a biopharmaceutical company focused on discovering, developing and delivering therapies for people living with neurological and neurodegenerative diseases as well as related therapeutic adjacencies.
Biogen Stock Soars on Alzheimer's Drug News BIIB also reported third quarter results Tuesday that easily beat the consensus both on the top and the bottom line. Oct 22, 2019 9:50 AM EDT
The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.. The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus
BIOGEN Income Statement, Balance Sheet and Statement of Cash Flows. BIOGEN News, charts, historical data, comparisons and more at Zacks Advisor Tools. Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM to treat plaque psoriasis.